Literature DB >> 14683595

Characterization of monoclonal antibody HTA125 with specificity for human TLR4.

Rong Wang1, Jeffrey Stephens, Michael J Lacy.   

Abstract

Binding of monoclonal antibody HTA125 to human toll-like receptor 4 (TLR4) was characterized by flow cytometry using MonoMac6 human monocytic cells. Data were obtained using direct binding to cell surface TLR4 by labeled HTA125, as well as inhibition of direct binding using purified reagents, and by two-step binding. HTA125 bound weakly to human TLR4, and could be inhibited by mouse Ig, mouse IgG Fc, and mouse IgG2a. In addition, purified human IgG Fc and purified human immunoglobulin of isotypes IgG1 and IgG4 could block binding of HTA125 to MonoMac6 cells. Furthermore, a mouse IgG1 monoclonal antibody possessing specificity for human CD64, which is a high affinity IgG Fc receptor, partially inhibited binding of HTA125 to MonoMac6 cells. Finally, co-stimulation via TLR4 and Fc receptor, resulted in cytokine production by MonoMac6 cells different than that induced via TLR4 alone. Therefore, the utility of HTA125 remains as a weak detector of human TLR4, and as an agent to block TLR4 ligands with an understanding that Fc receptor may be engaged also.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14683595     DOI: 10.1089/153685903771797057

Source DB:  PubMed          Journal:  Hybrid Hybridomics        ISSN: 1536-8599


  9 in total

1.  Adenovirus RIDalphabeta complex inhibits lipopolysaccharide signaling without altering TLR4 cell surface expression.

Authors:  Fernando Delgado-Lopez; Marshall S Horwitz
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

2.  CD14 Counterregulates Lipopolysacharide-Induced Tumor Necrosis Factor-α Production in a Macrophage Subset.

Authors:  Anja Grahnert; Ronald Weiss; Erik Schilling; Nancy Stanslowsky; Ulrich Sack; Sunna Hauschildt
Journal:  J Innate Immun       Date:  2019-01-17       Impact factor: 7.349

3.  Reduced frequency of a CD14+ CD16+ monocyte subset with high Toll-like receptor 4 expression in cord blood compared to adult blood contributes to lipopolysaccharide hyporesponsiveness in newborns.

Authors:  Sigifredo Pedraza-Sánchez; Amy G Hise; Lakshmi Ramachandra; Fabian Arechavaleta-Velasco; Christopher L King
Journal:  Clin Vaccine Immunol       Date:  2013-04-17

4.  HLA class I antibodies trigger increased adherence of monocytes to endothelial cells by eliciting an increase in endothelial P-selectin and, depending on subclass, by engaging FcγRs.

Authors:  Nicole M Valenzuela; Arend Mulder; Elaine F Reed
Journal:  J Immunol       Date:  2013-05-20       Impact factor: 5.422

5.  Involvement of mitogen-activated protein kinases and NFkappaB in LPS-induced CD40 expression on human monocytic cells.

Authors:  Weidong Wu; Neil E Alexis; Xian Chen; Philip A Bromberg; David B Peden
Journal:  Toxicol Appl Pharmacol       Date:  2007-12-14       Impact factor: 4.219

6.  Characterization of NF-κB Reporter U937 Cells and Their Application for the Detection of Inflammatory Immune-Complexes.

Authors:  Csilla Kecse-Nagy; Zoltán Szittner; Krisztián Papp; Zoltán Hegyi; Paolo Rovero; Paola Migliorini; Veronika Lóránd; László Homolya; József Prechl
Journal:  PLoS One       Date:  2016-05-27       Impact factor: 3.240

Review 7.  Monoclonal Antibody to CD14, TLR4, or CD11b: Impact of Epitope and Isotype Specificity on ROS Generation by Human Granulocytes and Monocytes.

Authors:  Dmitry S Kabanov; Sergey V Grachev; Isabella R Prokhorenko
Journal:  Oxid Med Cell Longev       Date:  2020-11-20       Impact factor: 6.543

8.  Mycobacteria attenuate nociceptive responses by formyl peptide receptor triggered opioid peptide release from neutrophils.

Authors:  Heike L Rittner; Dagmar Hackel; Philipp Voigt; Shaaban Mousa; Andrea Stolz; Dominika Labuz; Michael Schäfer; Michael Schaefer; Christoph Stein; Alexander Brack
Journal:  PLoS Pathog       Date:  2009-04-03       Impact factor: 6.823

9.  Lipopolysaccharide induces IFN-γ production in human NK cells.

Authors:  Leonid M Kanevskiy; William G Telford; Alexander M Sapozhnikov; Elena I Kovalenko
Journal:  Front Immunol       Date:  2013-01-28       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.